Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus NEOPHAM 6 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus NEOPHAM 6 4.
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER vs NEOPHAM 6.4%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 4.25% w/ Electrolytes in Dextrose 25% is a parenteral nutrition formulation providing amino acids for protein synthesis and dextrose as a carbohydrate calorie source. The amino acids serve as substrates for protein synthesis, while dextrose provides glucose for cellular energy metabolism via glycolysis and the citric acid cycle. Electrolytes are included to maintain acid-base and fluid balance, and to support enzymatic functions and membrane potentials.
NEOPHAM 6.4% is a sterile, nonpyrogenic, hypertonic solution of amino acids and glycerin used for parenteral nutrition. It provides essential and non-essential amino acids to support protein synthesis and energy metabolism, with glycerin serving as a non-glucose caloric source to reduce hyperglycemia. The amino acids are utilized for tissue repair and growth, while glycerin is metabolized via gluconeogenesis and glycolysis.
Intravenous infusion. Adult dose: 500 mL to 1000 mL per 24 hours, adjusted to meet protein and calorie requirements. Typical infusion rate: 1.5-2.0 mL/kg/hour, not exceeding 3.0 mL/kg/hour.
Intravenous infusion of 6.4% amino acid solution at 0.8-1.5 g/kg/day (equivalent to 12.5-23.4 mL/kg/day) for protein replenishment; typical adult dose 500-1000 mL/day infused at 1-2 mL/min.
None Documented
None Documented
Not applicable as a single entity; amino acids have rapid turnover (minutes to hours) with no terminal half-life. Dextrose has a half-life of 15-20 minutes under steady-state conditions.
Not applicable as a single entity; amino acids have varying half-lives (minutes to hours depending on individual amino acid and metabolic state). Clinical context: continuous infusion used for parenteral nutrition; no terminal elimination half-life defined for the mixture.
Amino acids are metabolized to urea (liver) and CO2; nitrogen is excreted renally as urea (80-90%), with minimal (<5%) biliary/fecal. Dextrose is metabolized to CO2 (exhaled) and water. Electrolytes are excreted renally proportional to intake and homeostasis.
Renal elimination of absorbed amino acids and metabolites; minimal biliary/fecal excretion. >90% of infused amino acids are reincorporated into body protein or metabolized; excess nitrogen excreted as urea in urine.
Category C
Category C
Amino Acid Solution
Amino Acid Solution